Breast Video Channel
Explore the latest insights and summaries from experts in Breast.
Therapeutic Agents
Nebraska Oncology Society
Early Stage TNBC Updates
FEATURING
Jairam Krishnamurthy
- 102 views
- April 9, 2024
- 1
Nebraska Oncology Society
2024 Updates in mTNBC
FEATURING
Jairam Krishnamurthy
- 121 views
- April 10, 2024
- 1
London Breast Meeting
Updates in Systemic Therapy in mBC
FEATURING
Cornelia Leo
- 51 views
- April 16, 2024
- 1
London Breast Meeting
IO in Breast Cancer: Harnessing the Power of the Immune System
FEATURING
Alicia Okines
- 39 views
- April 16, 2024
Cedars Sinai
Management of Toxicities Associated With Targeted Agents in Stage 4 HR+/HER2- BC
FEATURING
Yuan Yuan
- 275 views
- April 18, 2024
- 2
Cedars Sinai
Unmet Need in HR+/HER2- mBC: Resistance to 1L CDK4/6i and ET
FEATURING
Yuan Yuan
- 420 views
- April 18, 2024
- 2
ecancer
KEYNOTE-756 Trial - Adding Pembro to Chemo Before and After BC Surgery
FEATURING
Javier Cortes
- 341 views
- April 23, 2024
- 2
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Successes and Challenges of Early Drug Development for Brain Metastasis
FEATURING
Alex Drilon
- 302 views
- April 30, 2024
- 2
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Breast Cancer Brain Metastases: From a Medical Oncologist’s Perspective
FEATURING
Rebecca Dent
- 344 views
- April 30, 2024
- 4
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Frontiers in Breast Cancer Brain Metastasis: ADC Effectiveness in the CNS
FEATURING
Shanu Modi
- 285 views
- April 30, 2024
- 3
University of Colorado Cancer Center
Optimal Treatment for Early Stage HER2+ BC: Tailoring Treatment to Response
FEATURING
Virginia Borges
- 346 views
- May 1, 2024
- 4
Lilly Medical Affairs
SERDS: Relevance and Role in Current & Future Treatments for HR+, HER2- MBC
FEATURING
Komal Jhaveri
- 751 views
- July 24, 2024
- 7
Lilly Medical Affairs
CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC
FEATURING
Joyce O’Shaughnessy
- 2,384 views
- July 24, 2024
- 13
Sara Tolaney
ASCO® 2024 Noteworthy Abstracts in Breast Cancer
FEATURING
Hope Rugo
- 932 views
- May 24, 2024
- 10
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Summary: "Community Oncologists Highlights"
FEATURING
Sara Tolaney,
Hope Rugo
- 1,124 views
- May 24, 2024
- 11
Insights from ESMO Breast 2024 Annual Meeting
ESMO Breast 2024 Summary: "Rapid Insights"
FEATURING
Sara Tolaney,
Hope Rugo
- 59 views
- May 28, 2024
University of Illinois Cancer Center
Clinical Guidance on the Management and Monitoring of T-DXd-Related Adverse Events in HER2+ mBC
FEATURING
V.K. Gadi
- 304 views
- May 28, 2024
- 3
COR2ED The Heart of Medical Education
54 y/o Postmenopausal Woman ER+ mBC Case Discussion: Elacestrant and Beyond
FEATURING
Maria Vittoria Dieci
- 82 views
- June 4, 2024
COR2ED The Heart of Medical Education
Treating ER+/HER2-Low mBC: 2L and Beyond
FEATURING
Aditya Bardia
- 247 views
- June 4, 2024
- 5
Insights from ESMO Breast 2024 Annual Meeting
Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Award Lecture
FEATURING
Hope Rugo
- 1,205 views
- June 7, 2024
- 10
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "ACE-Breast-02 Trial - ARX788 vs. Lapatinib + Capecitabine in HER2+ ABC"
FEATURING
Xi-Chun Hu
- 49 views
- June 12, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "H3B-6545 in Women With ER+/HER2- mBC"
FEATURING
Erika Hamilton
- 27 views
- June 18, 2024
ecancer
ASCO® 2024 Insights: "I-SPY2.2 Trial - Pathologic Response to Neoadjuvant Datopotamab Deruxtecan in Breast Cancer"
FEATURING
Jane Meisel
- 235 views
- June 20, 2024
Miami Cancer Institute Precision Oncology Symposium
Incorporating IO and Emerging Therapeutic Strategies for mTNBC
FEATURING
Reshma L. Mahtani
- 148 views
- July 2, 2024
Miami Cancer Institute Precision Oncology Symposium
HER2 Targeted Treatments in Lower BC Expression Ranges
FEATURING
Ian Krop
- 225 views
- July 2, 2024
- 2
Miami Cancer Institute Precision Oncology Symposium
Precision Therapy for HR+/HER2- mBC
FEATURING
Joyce O'Shaughnessy
- 517 views
- July 2, 2024
- 7
Mattea Reinisch
Real-World Management of Patients With mTNBC Receiving Sacituzumab Govitecan
- 221 views
- July 4, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive & Clinical Implications"
FEATURING
Sara Tolaney,
Hope Rugo
- 932 views
- July 4, 2024
- 5
UChicago Medicine
Advances in Targeted and Endocrine Therapies for Metastatic HR+/HER2- Breast Cancer
FEATURING
Nan Chen
- 523 views
- July 11, 2024
- 3
Integrity CE
Clinical Roundtable: HR+ BC Early Stage & Metastatic Disease Updates
- 238 views
- August 2, 2024
- 1
Avan Armaghani
ASCO® 2024 Review: Treatment Updates on TNBC and HR+/HER2- Breast Cancer
- 279 views
- August 9, 2024
- 2
Adrienne Waks
New Insights Into Optimizing HER2-Directed Therapy in the Curative Setting
- 203 views
- August 13, 2024
- 2
Seth Wander
Serial CDK4/6 Inhibitor Therapy for HR+-HER2- MBC: Evolving Insights, Key Questions, and Ongoing Studies
- 561 views
- August 13, 2024
- 5
University of Illinois Cancer Center
Key Updates and Insights on HER2+ Breast Cancer
FEATURING
V.K. Gadi
- 176 views
- August 20, 2024
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Updates in mBC
FEATURING
Sudha Yarlagadda
- 85 views
- August 27, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO 2024 Highlights: Insights From Key Abstracts on mBC
FEATURING
Sramila Aithal
- 191 views
- August 27, 2024
- 2
Alessia Pellerino
Treatment Strategies for Leptomeningeal Disease in HER2+ mBC: Addressing Unmet Needs
- 163 views
- August 29, 2024
- 2
Katarzyna Jerzak
Advancements in Treatment Strategies for HR+/HER2- mBC: Current and Future Perspectives
- 187 views
- August 29, 2024
- 1
Stanford Medicine
Hot Flashes: Nonhormonal Options for Cancer Patients
FEATURING
Milana Dolezal
- 321 views
- September 18, 2024
- 5
Houston Methodist
Early Interception in Breast Cancer: Organ Preservation and Avoidance of Systemic Side Effect
FEATURING
Pamela Munster
- 21 views
- September 18, 2024
Patrick Neven
Patient Selection for Adjuvant Abemaciclib in HR+/HER2- eBC
- 192 views
- September 19, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: PROMENADE Trial - Pembro for Early ER-Low/HER2- BC - Real World French Cohort
FEATURING
Francois Cherifi
- 89 views
- September 23, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro or Placebo + CT in High-Risk Early TNBC - OS Results From KEYNOTE-522
FEATURING
Heather McArthur
- 157 views
- September 24, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CAPItello-290 Trial - Capivasertib + Paclitaxel as 1L Treatment for mTNBC
FEATURING
Heather McArthur
- 140 views
- September 24, 2024
- 1
Miguel Abreu
monarchE Study: The Impact of Dose Reductions on Abemaciclib Efficacy in High-Risk eBC
- 392 views
- September 26, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: IBI354 - Anti-HER2 ADC in Advanced Solid Tumors and Breast Cancer
FEATURING
Christina Teng
- 76 views
- October 1, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: T-DXd in HER2+ mBC With or Without Brain Metastases - DESTINYBreast-12 Primary Results
FEATURING
Nancy Lin
- 214 views
- October 8, 2024
- 1
Priya Tiwari
Benefits of Oral Formulations in HR+/HER2- mBC: Reducing Time Toxicity and Improving Well-Being
- 503 views
- October 9, 2024
- 2
ecancer
ESMO 2024 Insights: Neo-CheckRay Trial - Durvalumab & Oleclumab Boost for SBRT + Chemo in ER+/HER2- eBC
FEATURING
Alex De Caluwe
- 16 views
- October 11, 2024
ecancer
ESMO 2024 Insights: WSG-TP-II Trial - ET + Trastuzumab & Pertuzumab vs. De-Escalated Chemo + Trastuzumab & Pertuzumab in HR+/HER2+ eBC
FEATURING
Oleg Gluz
- 43 views
- October 11, 2024
- 1
Fernanda Mosele
Trastuzumab Deruxtecan's Efficacy Across HER2 Expression Levels in mBC: Key Results From the DAISY Trial
- 373 views
- October 16, 2024
- 3
Jan-Willem Henning
NATALEE Trial Impact on eBC: Ribociclib + ET as Adjuvant Treatment in Patients With HR+/HER2- Disease
- 488 views
- October 21, 2024
- 5
Yale Cancer Center
Key Trials and Updates in Breast Cancer: Expert Insights
FEATURING
Maryam Lustberg
- 193 views
- October 21, 2024
- 4
Jan-Willem Henning
monarchE Trial & High-Risk eBC: Efficacy, Safety, QoL, and Biomarker Analysis
- 131 views
- October 22, 2024
Claudine Isaacs
mBC Updates: DESTINY-Breast06 Trial - 1L T-DXd vs. Chemo in HR+ HER2-Low & HER2-Ultralow Disease
- 233 views
- November 4, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TroFuse-010 Trial - Sacituzumab Tirumotecan ± Pembro vs. Chemo in HR+/HER2- Advanced BC
FEATURING
Sara Tolaney
- 262 views
- November 4, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Adjuvant Ribociclib + NSAI in HR+/HER2- eBC - 4-Year Outcomes From the NATALEE Trial
FEATURING
Peter Fasching
- 70 views
- November 19, 2024
- 1
Sara Tolaney
SABCS 2024 Noteworthy Abstracts in Metastatic Breast Cancer
FEATURING
Hope Rugo
- 675 views
- November 19, 2024
- 6
Antonio Llombart Cussac
Integrating HER2-Low Targeted Therapies Into the Luminal mBC Treatment Landscape
- 144 views
- November 20, 2024
- 1
Junji Tsurutani
Impact of T-Dxd Approval on HER2-Low mBC Treatment and Patient Outcomes
- 169 views
- November 25, 2024
- 2
Kirollos Hanna
Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC
- 2,264 views
- July 19, 2024
- 5
Yale Cancer Center
Innovations in Breast Medical Oncology: Immunotherapy in eBC
FEATURING
Kathleen Fenn
- 27 views
- November 13, 2024
UChicago Medicine
Neoadjuvant & Adjuvant Therapy for High-Risk, Early Stage TNBC
FEATURING
Rita Nanda
- 255 views
- March 1, 2024
- 5
UChicago Medicine
Neoadjuvant & Adjuvant Therapy for HER2+, High-Risk, Early Stage BC
FEATURING
Rita Nanda
- 298 views
- March 1, 2024
- 1
UChicago Medicine
2024 Neoadjuvant IO Updates for HR+ BC
FEATURING
Gini Fleming
- 123 views
- March 1, 2024
- 1
Total Health
Immune Checkpoint Inhibitors and Neoadjuvant Chemo for HR+ BC: Year in Review
FEATURING
Cynthia Ma
- 235 views
- March 2, 2024
UChicago Medicine
Advanced ER+ BC: Novel Endocrine Agents Such as ER PROTACs and ER CERANs With Promising Early Phase Data
FEATURING
Nan Chen
- 103 views
- March 4, 2024
- 2
UChicago Medicine
Advanced HR+ BC: Elacestrant vs. ET, Alpelisib/Inavolisib for PIK3CAm Tumors, Capivasertib for AKT Pathway-Altered Tumors
FEATURING
Nan Chen
- 222 views
- March 4, 2024
- 1
UChicago Medicine
New and Emerging CDK4/6i Therapies for Advanced HR+ BC
FEATURING
Nan Chen
- 338 views
- March 4, 2024
- 6
UChicago Medicine
ADCs in Breast Cancer: Ongoing Trials and Future Directions
FEATURING
Hope Rugo
- 48 views
- March 4, 2024
UChicago Medicine
2024 Updates on ADCs in HER2-Low, HR+, and TNBC
FEATURING
Hope Rugo
- 201 views
- March 4, 2024
- 3
UChicago Medicine
Antibody Drug Conjugates: Overview and Background of a Revolution in Breast Cancer Treatment
FEATURING
Hope Rugo
- 541 views
- March 4, 2024
- 4
University of Louisville
Role of m6A in RNA Transcripts in Endocrine-Therapy Resistance in Breast Cancer Cells
FEATURING
Carolyn Klinge
- 13 views
- March 12, 2024
Total Health
Current Adjuvant Treatment in HR+ BC
FEATURING
Gregory Vidal
- 156 views
- March 12, 2024
- 2
Total Health
Current Adjuvant Treatment in HER2+ BC
FEATURING
Gregory Vidal
- 253 views
- March 12, 2024
- 1
Total Health
ADCs in Breast Cancer: Datopotamab Deruxtecan Overview
FEATURING
Heather McArthur
- 173 views
- March 12, 2024
- 3
Total Health
ADCs in Breast Cancer: Sacituzumab Govitecan Overview
FEATURING
Heather McArthur
- 147 views
- March 12, 2024
- 1
Total Health
ADCs in Breast Cancer: Trastuzumab Emtansine Overview
FEATURING
Heather McArthur
- 21 views
- March 12, 2024
Total Health
Antibody Drug Conjugates: Future Applications in Breast Cancer
FEATURING
Kevin Kalinsky
- 234 views
- March 12, 2024
- 3
Total Health
Antibody Drug Conjugates: Highlights in Breast Cancer
FEATURING
Kevin Kalinsky
- 315 views
- March 12, 2024
- 1
Total Health
Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted Therapy in the 2L Setting
FEATURING
Ruth O'Regan
- 461 views
- March 12, 2024
- 2
Total Health
Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted Therapy in the 1L Setting
FEATURING
Ruth O'Regan
- 1,371 views
- March 12, 2024
- 4
Masonic Cancer Center, University of Minnesota
Lobular Carcinoma of the Breast: MDC1 & Gene Regulations
FEATURING
Matthew Sikora
- 10 views
- March 15, 2024
Scripps Health
CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC
FEATURING
Sarah Sammons
- 1,750 views
- March 19, 2024
- 10
Scripps Health
Anthracyclines for Early Stage Breast Cancer - Do They Still Have a Role?
FEATURING
Virginia Borges
- 1,347 views
- March 19, 2024
- 18
Integrity CE
TROP-2 ADCs for the Treatment of HR+/HER2- BC, TNBC, and NSCLC: Advancing Care in the Community Oncology Setting
FEATURING
Lee Schwartzberg,
Jason Porter
- 125 views
- March 20, 2024
- 1
Scripps Health
2024 Neuro-Oncology Update: Breast Cancer and Brain Mets
FEATURING
Tresa McGranahan
- 368 views
- April 2, 2024
- 3
London Breast Meeting
How to Avoid Lower Pole Stretch
FEATURING
Patrick Mallucci
- 28 views
- April 16, 2024
London Breast Meeting
How to Avoid Implant Lateralization and Casualization in an Unstable Implant
FEATURING
Charles Randquist
- 48 views
- April 16, 2024
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Chemoprevention in Brain Mets: Breast Cancer Perspective
FEATURING
Alexandra Zimmer
- 263 views
- April 30, 2024
- 7
University of Colorado Cancer Center
Type 2 Diabetes Risk With Endocrine Therapies for Breast Cancer
FEATURING
Rebecca Scalzo
- 18 views
- May 9, 2024
Total Health
The Role of Radiation Therapy in Oncology
FEATURING
Ryan Lanning
- 116 views
- July 1, 2024
Stanford Medicine
Sexual Health and Wellbeing in Women’s Cancer Survivors
FEATURING
Milana Dolezal
- 217 views
- July 10, 2024
- 4
Cleveland Clinic Taussig Cancer Institute
Options for Breast Neurotization: How I Do It
FEATURING
Ziv Peled
- 40 views
- September 3, 2024
Cleveland Clinic Taussig Cancer Institute
Bone Health in Premenopausal Women With Early BC Receiving ET
FEATURING
Sabashini Ramchand
- 134 views
- September 6, 2024
- 3
Cleveland Clinic Taussig Cancer Institute
Endocrine Therapy in Young Women With Early BC
FEATURING
Erin Roesch
- 215 views
- September 6, 2024
- 4
Houston Methodist
Post Cryoablation Pathological Findings
FEATURING
Mary Schwartz
- 4 views
- October 8, 2024
Houston Methodist
Cryoablation for Breast Cancer: The Basics
FEATURING
Luz Venta
- 89 views
- October 8, 2024
- 1
Houston Methodist
Cryoablation - The Big Picture
FEATURING
Davood Abdollahian
- 137 views
- October 14, 2024
Houston Methodist
Cryoablation: Abscopal Effect & Immune Therapy
FEATURING
Robert Ward
- 8 views
- October 14, 2024
Yale Cancer Center
Identifying and Targeting DNA Repair Mutations in Cancer
FEATURING
Shridar Ganesan
- 30 views
- October 14, 2024
Yale Cancer Center
Radiation Therapy in Breast Cancer Treatment
FEATURING
Susan Higgins
- 13 views
- November 25, 2024
University of Illinois Cancer Center
ADC Therapy for Metastatic HR+/HER2- BC
FEATURING
V.K. Gadi
- 4 views
- December 6, 2024
University of Illinois Cancer Center
Metastatic HR+/HER2- BC: CDK4/6 Inhibitor Insights and Next-Line Treatment Options
FEATURING
V.K. Gadi
- 62 views
- December 6, 2024
2024 SABCS Annual Meeting Insights Hub
SABCS 2024 Insights: EmpowHER 303 - Zanidatamab vs. Trastuzumab + Chemo in HER2+ mBC Post-T-DXd
FEATURING
Sara Tolaney
- 2 views
- December 17, 2024
